Welcome to our dedicated page for In8Bio SEC filings (Ticker: INAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
New data drops, trial amendments, and sudden capital raises make In8Bio’s SEC filings dense—even seasoned biotech investors can miss a key footnote hidden in a 300-page 10-K. If you have ever asked, “How do I keep up with In8Bio insider trading Form 4 transactions or trial updates disclosed at midnight?”, this page is built for you.
Stock Titan’s AI reads every line the moment an 8-K hits EDGAR, then serves plain-English highlights so you can start understanding In8Bio SEC documents with AI instead of combing through jargon. Whether it’s an In8Bio quarterly earnings report 10-Q filing breaking down R&D cash burn, an In8Bio proxy statement executive compensation outlining option grants, or an In8Bio annual report 10-K simplified to show pipeline timelines, the platform connects each disclosure to what matters for a clinical-stage oncology company.
Use our real-time alerts to monitor In8Bio Form 4 insider transactions real-time and spot patterns in In8Bio executive stock transactions Form 4. Dive into AI-tagged sections that map trial phase progress, safety data, and convertible note terms—crucial insights typically buried deep inside filings. Need context on a sudden press release? The companion 8-K is already summarized under In8Bio 8-K material events explained. From pipeline-specific risk factors to cash-runway projections, our In8Bio earnings report filing analysis turns complex disclosures into actionable knowledge so you can focus on decisions, not documents.
Cellectar Biosciences (Nasdaq: CLRB) filed Amendment No. 1 to its Form S-1 on 30 June 2025, seeking to register a follow-on public offering of up to 755,667 Class A Units or, at investors’ election, an equal number of Class B Units. Each Class A Unit contains one share of common stock and one five-year common warrant; each Class B Unit substitutes the share with a pre-funded warrant priced at $0.00001 to mitigate ownership-limit issues (4.99% or 9.99% caps).
The filing covers up to 1,556,674 shares issuable upon exercise of pre-funded, common and representative warrants, plus an underwriters’ 45-day over-allotment option for up to 113,350 additional shares and/or warrants. Representative warrants equal to 6% of units sold will also be issued. The assumed public offering price is $7.94, the last closing price on 25 June 2025; final pricing will be set through negotiation with lead underwriter Ladenburg Thalmann.
On 24 June 2025 the company completed a 1-for-30 reverse stock split, leaving authorized share count and par value unchanged. Following the split, Cellectar remains a non-accelerated filer and smaller reporting company. The S-1 reiterates that investing in the securities involves a “high degree of risk,” directing readers to a dedicated Risk Factors section starting on page 17. Proceeds, net of underwriting fees and expenses, are not quantified here and will depend on final pricing and warrant exercise, while the company reserves the right to delay effectiveness until it files a further amendment.
FAQ
What is the current stock price of In8Bio (INAB)?
What is the market cap of In8Bio (INAB)?
What is the primary focus of In8Bio, Inc.?
How does In8Bio approach cancer treatment differently?
Which types of cancers does In8Bio target?
What makes the company’s technology innovative?
How does In8Bio ensure the safety of its therapies?
In what stage of development is In8Bio’s therapy pipeline?
How does In8Bio differentiate itself from other biopharmaceutical companies?
What benefits do gamma-delta T cells offer in cancer treatment?
